GSK Reports Improved Outlook Despite U.S. Drug Tariffs

British pharmaceutical giant GlaxoSmithKline (GSK) has raised its 2025 financial outlook, citing strong second-quarter performance in cancer drug sales—despite facing new U.S. tariffs, Agence France-Presse (AFP) reported.

GSK expects to finish the year “towards the top end” of its guidance and remains confident in its long-term prospects. I Photo: GSK Facebook

GSK, which manufactures medicines in the EU, UK, and U.S., said its updated guidance accounts for the 15% tariffs outlined in the recent EU–U.S. trade agreement.

However, there are concerns Washington could still impose higher tariffs on some medicines despite the deal.

Nevertheless, GSK CEO Emma Walmsley said the company expects to finish the year “towards the top end” of its guidance and remains confident in its long-term prospects.

“GSK’s strong momentum in 2025 continues with another quarter of excellent performance,” Walmsley said. “Specialty medicines—our largest business—led the way, with double-digit sales growth in respiratory, immunology and inflammation, oncology, and HIV.”